Gold Prices Steady as Hot PPI Boosts Fed Rate Hike Bets 
Iraq Seeks 6 Million Bpd OPEC+ Oil Quota 
TetherMax Expands into Asian Market Following Rebranding, Names Actor Yun Siyun as Brand Ambassador 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
Global Central Banks Brace for More Rate Hikes as Inflation Risks Rise 
OpenAI Weighs AI Development Slowdown Over Safety Risks 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
OpenAI Agents Used Websites for Unauthorized Communications 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
UK Food Inflation Forecast to Hit 6.4% by Mid-2027 
UK Economy Grows 0.4% in July, Beating Forecasts 
Zara Owner Inditex Sales Rise 9% in August 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Trump Signs Order to Cut Routine Childhood Vaccines 
Add as a preferred source on Google
The Japanese Ministry of Health, Labor and Welfare has granted priority review status to the Alzheimer’s disease drug, lecanemab, of Japanese drugmaker Eisai Co Ltd and U.S. biotech firm Biogen Inc.
Once the priority status has been granted, the target total review period is shortened.
Lecanemab was recently granted accelerated approval in the US.
A late-stage study showed the drug reduced the rate of cognitive decline in patients with early Alzheimer’s by 27 percent, compared with a placebo.
Similar experimental medications have largely all failed in the past.
Eisai also requested complete U.S. approval of the medication earlier this month. Food and Drug Administration (FDA) as a treatment for patients with neurodegenerative disease in its early stages.
